News
September 20, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced important new real-world evidence confirming XARELTO® (rivaroxaban) reduced the risk of recurrent venous thromboembolism (VTE) – or blood clots – in patients who are morbidly obese, with effectiveness and safety similar to warfarin.
September 18, 2019
Despite advances in medical imaging, the mechanisms leading to the irregular contractions of the heart during heart rhythm disorders remain poorly understood.
September 18, 2019
EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the WiSE CRT System for the treatment of heart failure.
September 17, 2019
Instem, a leading provider of IT solutions to the global life sciences marke
September 11, 2019
…
September 6, 2019
The OrthoVest is a personal protective device in use at several facilities and is currently undergoing testing in the cardiac electrophysiology (EP) lab at th
September 6, 2019
BioSig Technologies, Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, announced that its subsidiary, NeuroClear Technologies, Inc., raised $3.7 million in an initial seed round.